- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05319795
Effortful Swallow Maneuver for Swallowing Impairment in People With Parkinson Disease
Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With Parkinson Disease
Context: Many people with Parkinson Disease (PwPD) experience swallowing difficulties, particularly with food/liquid going down the wrong way or remaining in the throat after swallowing. Prior studies suggest that exercise-based treatments targeting swallowing strength may be effective in reducing these difficulties.
Research question: Does an exercise-based treatment involving the effortful swallow maneuver improve swallowing function in PwPD?
Study plan: The investigators will study the effects of a four-week intensive swallowing rehabilitation program in PwPD, over a 2-year period.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will study the effects of a four-week intensive swallowing rehabilitation program in PwPD, over a 2 year period. The program will involve daily practice of the effortful swallowing maneuver, with swallowing function assessed before and after the treatment program using videofluoroscopic x-rays.
Expected outcomes: In other populations, the effortful swallow has shown to address two mechanisms that are thought to underlie swallowing impairment in Parkinson Disease: slowness in achieving airway protection and weakness in muscles responsible for transporting food through the throat. The investigators expect that repeated practice of this maneuver by PwPD will lead to improved airway protection and improved clearance of residue from the throat.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
Toronto, Ontario, Canada, M5G 2A2
- Toronto Rehabilitation Institute - University Health Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years old
- English-speaking
- Able to follow study instructions
- Neurologist confirmed diagnosis of PD
- Hoehn and Yahr scale score of 2 or 3
Self-report of one or more swallowing or related symptoms:
- Difficulty with secretion management
- Coughing at the meal time
- Choking on food
- Respiratory infection in the past 6 months (other than COVID)
Exclusion Criteria:
- History of head and neck cancer
- Radical neck dissection (e.g. anterior cervical spine surgery) or neck/ oropharyngeal surgery (not excluded - tonsillectomy, adenoidectomy)
- Past medical history of any neurological disease other than PD (e.g. multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, stroke)
- Cognitive or receptive communication difficulties that preclude the participant's ability to follow study instructions provided in English. This will be determined by the participant's physician prior to referring them to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Effortful Swallow Maneuver
Adults with a confirmed diagnosis of Parkinson Disease who have radiographically confirmed difficulties with timely airway protection and/or bolus clearance during swallowing.
Individuals will complete a 4-week intervention program with two 30-minute sessions of Effortful Swallow (ES) practice daily, 5 days per week.
|
Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Time-to-laryngeal-vestibule-closure Thin Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
The time interval (in milliseconds) measured on a videofluoroscopic x-ray of swallowing between onset of the hyoid burst movement at the beginning of a swallow and achieving airway protection via closure of the laryngeal vestibule.
The investigators will measure time-to-laryngeal-vestibule-closure across a series of 3 thin liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
longest) across these 3 task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Penetration-Aspiration Scale Score Thin Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
The Penetration-Aspiration Scale is an 8-point ordinal scale, measured on a videofluorosopic x-ray of swallowing, which documents the depth of any airway invasion events, and the subsequent response to airway invasion (Rosenbek et al., 1996).
The scale ranges from a minimum score of 1 (no airway invasion) to a maximum score of 8 (entry of material below the true vocal folds with no response and no ejection).
Higher scores are worse.
The investigators will measure penetration-aspiration across a series of 3 thin liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
highest) across these three task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Pharyngeal Area at Maximum Constriction Thin Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
A videofluoroscopic measure of the degree of pharyngeal constriction during swallowing (i.e.
maximum obliteration of the space in the pharynx).
This measure is obtained from pixel-based measures of the unobliterated area of the pharynx on a lateral view x-ray image at the point of maximum constriction.
The number of pixels is divided by an anatomical reference scalar defined by the squared length of the distance, in pixels, between the anterior inferior corners of the C2 and C4 cervical vertebrae on the same image.
The investigators will measure pharyngeal area at maximum constriction across a series of 3 thin liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
largest) across these three task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Total Pharyngeal Residue Thin Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
A videofluoroscopic measure of the amount of residue left behind in the pharynx after a swallow.
This measure is obtained from pixel-based measures of the area of residue in the pharynx on a lateral view x-ray image at the end of the swallow.
The number of pixels is divided by an anatomical reference scalar defined by the squared length of the distance, in pixels, between the anterior inferior corners of the C2 and C4 cervical vertebrae on the same image.
The investigators will measure pharyngeal residue across a series of 3 thin liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
largest) across these three task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Time-to-laryngeal-vestibule-closure Mildly Thick Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
The time interval (in milliseconds) measured on a videofluoroscopic x-ray of swallowing between onset of the hyoid burst movement at the beginning of a swallow and achieving airway protection via closure of the laryngeal vestibule.
The investigators will measure time-to-laryngeal-vestibule-closure across a series of 3 mildly thick liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
longest) across these 3 task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Penetration-Aspiration Scale Score Mildly Thick Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
The Penetration-Aspiration Scale is an 8-point ordinal scale, measured on a videofluorosopic x-ray of swallowing, which documents the depth of any airway invasion events, and the subsequent response to airway invasion (Rosenbek et al., 1996).
The scale ranges from a minimum score of 1 (no airway invasion) to a maximum score of 8 (entry of material below the true vocal folds with no response and no ejection).
Higher scores are worse.
The investigators will measure penetration-aspiration across a series of 3 mildly thick liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
highest) across these three task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Pharyngeal Area at Maximum Constriction Mildly Thick Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
A videofluoroscopic measure of the degree of pharyngeal constriction during swallowing (i.e.
maximum obliteration of the space in the pharynx).
This measure is obtained from pixel-based measures of the unobliterated area of the pharynx on a lateral view x-ray image at the point of maximum constriction.
The number of pixels is divided by an anatomical reference scalar defined by the squared length of the distance, in pixels, between the anterior inferior corners of the C2 and C4 cervical vertebrae on the same image.
The investigators will measure pharyngeal area at maximum constriction across a series of 3 mildly thick liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
largest) across these three task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
|
Change in Total Pharyngeal Residue Mildly Thick Liquids
Time Frame: Post treatment (4 weeks) compared to pre-treatment baseline
|
A videofluoroscopic measure of the amount of residue left behind in the pharynx after a swallow.
This measure is obtained from pixel-based measures of the area of residue in the pharynx on a lateral view x-ray image at the end of the swallow.
The number of pixels is divided by an anatomical reference scalar defined by the squared length of the distance, in pixels, between the anterior inferior corners of the C2 and C4 cervical vertebrae on the same image.
The investigators will measure pharyngeal residue across a series of 3 mildly thick liquid swallows in videofluoroscopy.
The participant's worst score (i.e.
largest) across these three task repetitions will be recorded at each timepoint and the difference across timepoints will be calculated.
|
Post treatment (4 weeks) compared to pre-treatment baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Catriona M Steele, PhD, University Health Network, Toronto
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAPCR 21-5814
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Effortful Swallow Maneuver
-
Cairo UniversityNot yet recruiting
-
University of BaghdadNot yet recruiting
-
University of MichiganMichigan State University; One Mind InstituteCompleted
-
Northwestern UniversityNorthwestern Memorial HospitalCompletedHead and Neck Cancer | Dysphagia | Oropharyngeal Dysphagia | Oropharynx Squamous Cell CarcinomaUnited States
-
National Taiwan University HospitalUnknown
-
National Taiwan University HospitalCompletedNasopharyngeal Cancer | DysphagiaTaiwan
-
Shanghai Zhongshan HospitalNot yet recruitingSwallowing Training on Muscle Strength
-
Midwestern UniversityNorthwestern UniversityWithdrawnVertigo | Vestibular DiseaseUnited States
-
Chonbuk National UniversitySeoul National University Bundang HospitalCompletedHC-BPPVKorea, Republic of
-
Tactile MedicalTerminatedHead and Neck LymphedemaUnited States